Laboratory Corporation of America Holdings provided earnings guidance for the year 2021. For the year, the company expected a change in revenue for the enterprise of minus 1% to plus 4.5% compared to 2020 revenue of $14 billion. This guidance range also includes the expectation that the Base Business will grow 11% to 13.5% over 2020 revenue of $11.2 billion, while COVID testing revenue will decline 35% to 50%. Company expected a decline in revenue for Diagnostics of minus 0.5% to minus 7.5% compared to 2020 revenue of $9.3 billion. This guidance range includes the expectation that the Base Business will grow 11% to 14% over 2020 revenue of $6.5 billion, while COVID testing revenue will decline 35% to 50%. Company expect Drug Development revenue to grow 8% to 10.5% over 2020 revenue of $4.9 billion. This guidance range also includes the expectation that the Base Business will grow 9.5% to 12% over 2020 revenue of $4.8 billion despite the continuing negative impact from the pandemic.